Antibody response to mRNA SARS-CoV-2 vaccination in 182 patients after allogeneic hematopoietic cell transplantation.

Astrid Beerlage Karoline LeuzingerLuca ValoreRoby MathewTill JunkerBeatrice Drexler Jakob R Passweg Hans H Hirsch Joerg P Halter

Published in: Transplant infectious disease : an official journal of the Transplantation Society (2022)

While patients undergoing allogeneic stem cell transplantation have been excluded from the initial registration trials, our real-world experience with a large patient cohort confirms the data of previous studies, showing that most patients do have a good response to mRNA vaccines against SARS-CoV-2. Nevertheless, a significant proportion of patients shows an inadequate vaccination, which can be improved after a third vaccination in most cases despite immunosuppressive therapy.

Keyphrases

stem cell transplantation
sars cov
end stage renal disease
ejection fraction
newly diagnosed
patients undergoing
prognostic factors
high dose
bone marrow
case report
machine learning
patient reported outcomes
respiratory syndrome coronavirus